・As per Reuters, both the drugs have multibillion-dollar potential. ・FDA expects Merck to submit its applications for Enlicitide in April and for Sac-TMT in October or November next year. ・Other drugs ...
The FDA has introduced a new fast-track review system for three psychedelic drug programs targeting PTSD and depression, potentially cutting approval review times to one or two months once ...
The U.S. Food and Drug Administration (FDA) announced that it will fast-track review of nine experimental drugs. The move is part of a Trump administration program aimed at prioritizing medicines that ...
(CNN) — Some psychedelic drugs, once considered fringe, are now getting a step closer to possibly being approved for use as mental health treatments in the United States. The US Food and Drug ...
LEHI, Utah, June 15, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, today ...